Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track SION with free AI briefings, catalyst countdowns, and dilution alerts.

SION · Sionna Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$249.8M Cash on Hand
36.6mo Cash Runway
Follow SION by email Get an email when SION reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about SION, unsubscribe in one click. Privacy

📣 What SION Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
SION-719 Cystic Fibrosis (CF) Phase 2 · NCT07108153 Completed
SION-109 Cystic Fibrosis (CF) Phase 1 · NCT07035990 Completed
SION-2222 Cystic Fibrosis (CF) Phase 1 · NCT07035990 Completed
SION-451 Cystic Fibrosis (CF) Phase 1 · NCT07035990 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

SION holds $249.8M in cash and short-term investments (as of Sep 30, 2026) and burns about $20.5M/quarter from operations, an estimated runway of 36.6 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 10 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when SION files for a raise →

👥 Who Owns SION

Insiders 22.6% Other 5%+ holders 17.8% Institutions (209 holders) 59.6% Public and other holders 0%
HolderTypeShares% of sharesAs of
TPG GP A, LLC
10% owner
Insider 6,494,962 14.36% 2026-01-22
VIKING GLOBAL INVESTORS LP 5%+ holder (13G) 3,195,181 7.06% 2026-03-31
THE GOLDMAN SACHS GROUP, INC. Institution (13G, 5%+) 2,639,418 5.83% 2026-09-30
Enavate Sciences GP, LLC 5%+ holder (13D) 2,478,030 5.48% 2025-02-10
Peter A. Thompson
Director · +17,340 options
Insider 2,469,959 5.46% 2026-07-07
ORBIMED ADVISORS LLC
Director
Includes shares also reported by Peter A. Thompson, counted once
Insider 2,469,959 5.46% 2026-07-07
Atlas Venture Fund XI, L.P. 5%+ holder (13D) 2,382,495 5.27% 2025-10-16
Michael Cloonan
President & CEO, Director · +436,100 options
Insider 765,393 1.69% 2026-09-17
RA CAPITAL MANAGEMENT, L.P.
Director, 10% owner · +17,340 options
Insider 159,033 0.35% 2026-09-17
Elena Ridloff
CFO and CBO · +165,440 options
Insider 133,069 0.29% 2026-09-17
Charlotte McKee
CMO and Head of R&D · +155,700 options
Insider 128,415 0.28% 2026-09-17
Jennifer Fitzpatrick
CLO and Head of Program Mgmt. · +143,825 options
Insider 56,265 0.12% 2026-09-17

Share count 45,235,568 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full SION picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SION and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.